-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, AbbVie announced that the FDA approved Dalvance for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients (from birth to under 18)
ABSSSI is a bacterial infection of the skin and related tissues, mainly caused by Gram-positive bacteria, including Staphylococcus aureus (methicillin-sensitive and resistant strains, etc.
Dalbavancin is a second-generation semi-synthetic lipoglycopeptide antibiotic that inhibits the synthesis of bacterial cell walls
The FDA approval is based on the results of a multi-center, open-label, positive-controlled clinical trial and 3 pharmacokinetic studies to evaluate the safety and effectiveness of dalbavancin in pediatric patients
To evaluate the therapeutic effect of dalbavancin, 183 patients with ABSSSI in the modified intention-to-treat (mITT) population were analyzed
At present, a total of 7 new drugs for the treatment of ABSSSI have been approved for marketing worldwide, one is in the application for listing stage, and one is in the phase III clinical stage